Healthline: At-Home COVID-19 test gets FDA warning: What to know

UC infectious disease expert says the biggest risk is a false negative test

The Food and Drug Administration (FDA) announced recently that people should stop using the E25Bio rapid COVID-19 test. The agency warned that the test contains false labeling and instructions. The manufacturer  says the E25Bio test uses a “novel technology” that is more accurate than a PCR test “without the need for equipment and at a fraction of the cost and time.”

However, according to the FDA, this test hasn’t been “authorized, cleared, or approved” by the FDA for distribution or use in the United States and may include false labeling claiming that the test is authorized by the FDA.

In a story published by Healthline, Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was the only expert source cited, saying that in an emergency, manufacturers might rush a product to market and don’t have to deal with full FDA approval.

Dr. Fichtenbaum and Jassiel HIV study in lab.

Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine/Photo/Colleen Kelley/UC Creative + Brand

“Usually, this is uncommon as most retailers typically sell products that are FDA approved,” he added.

Fichtenbaum explained that the main danger is a false negative test.

“If someone really has COVID, and then assumes they don’t based upon a faulty or inaccurate test, they could infect others and become sicker themselves and not seek medical attention as quickly as they should,” he said.

According to Fichtenbaum, false positives can occur, and this could cause unnecessary concern and worry.

“Also, if people isolate, they might lose income or their job,” he continued.

The dangers associated with taking your own samples aren’t the biggest issue, Fichtenbaum said. The main concern is “inadequate” sample collection.

“People may not swab correctly or collect the right amount of saliva,” he said. “This can lower the effectiveness of the test and provide mostly false-negative results.”

Read the entire story here

Lead image/Boston 25 News

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

1

Ohio ranked No. 1 for business by CNBC

July 10, 2026

Ohio is CNBC’s No. 1 Top State for Business in 2026. The University of Cincinnati helps fuel that success through co-op, innovation, talent development and close collaboration with the state.

2

UC students organize free health clinic happening July 11-12

July 10, 2026

The University of Cincinnati student chapter of Remote Area Medical is holding its annual free health clinic July 11-12. The clinic is open to adults and children, with no income requirements. Anyone in the area who needs medical, dental or vision care will have a chance to get it for free, with no insurance required.

3

Hoxworth Blood Center CEO advocates on Capitol Hill during National Blood Advocacy Week

July 9, 2026

Hoxworth Blood Center, University of Cincinnati, has announced that David Oh, MD, director and chief executive officer, joined blood center leaders, patient advocates and partner organizations in Washington, D.C., in June as part of Blood Advocacy Week, a national initiative led by America’s Blood Centers to strengthen the nation’s blood supply.